Theracare Medicated Pain Relief Patches

Description

The drug is a Pain Relief Patch designed for transdermal delivery of analgesic agents. The effective time of the insert is March 1, 2023. The label features a referenced image of the medicated patch, providing a visual representation of the product.

Uses and Indications

This drug is indicated for the temporary relief of minor aches and pains.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children 12 years of age and over should begin by cleaning and drying the affected area thoroughly. The patch should then be removed from its protective film and applied directly to the affected area. It is recommended that the patch be applied no more than 3 to 4 times daily. Each application should not exceed 8 hours; the patch must be removed from the skin after this duration.

For children under 12 years of age, it is advised to consult a physician prior to use to determine appropriate treatment and dosage.

Contraindications

Use of this product is contraindicated in the following situations:

Application on wounds or damaged skin is prohibited due to the potential for irritation and adverse effects. The use of a heating pad concurrently is contraindicated as it may enhance absorption and increase the risk of systemic effects. Patients with known allergies to any ingredients in this product should avoid its use to prevent allergic reactions. Additionally, tight bandaging is not recommended, as it may impede circulation. Concurrent use with other topical analgesics is contraindicated to avoid potential additive effects and increased risk of adverse reactions.

Warnings and Precautions

Patients with a known allergy to aspirin or salicylates should consult a healthcare professional prior to using this product to avoid potential allergic reactions.

It is imperative to adhere to the following precautions to ensure safe use. The product should not be applied to wounds or damaged skin, as this may exacerbate irritation or lead to adverse effects. Additionally, the use of heating pads in conjunction with this product is contraindicated, as it may increase the risk of skin irritation or burns. Patients should also refrain from using the product if they are allergic to any of its ingredients.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (800-222-1222) should be contacted without delay.

Patients are advised to discontinue use and contact their healthcare provider if any of the following occur: the development of a rash, itching, or excessive skin irritation; worsening of the condition; or if symptoms persist beyond 7 days or resolve only to recur within a few days. These actions are crucial for ensuring patient safety and effective management of any adverse reactions.

Side Effects

Patients should be aware of the potential for allergic reactions when using this product, particularly if they have a history of sensitivity to aspirin or salicylates. It is advisable for these individuals to consult a healthcare professional prior to use.

In the event that patients experience a rash, itching, or excessive skin irritation, they should discontinue use and seek medical advice. Additionally, if the condition worsens or if symptoms persist for more than 7 days, or if symptoms resolve only to recur within a few days, it is important to consult a doctor. These recommendations are based on clinical observations and are intended to ensure patient safety and effective management of adverse reactions.

Drug Interactions

Concurrent use of this medication with other topical analgesics is contraindicated. The combination may increase the risk of adverse effects without providing additional therapeutic benefit. It is advised to avoid using multiple topical analgesics simultaneously to ensure patient safety and optimal therapeutic outcomes. Monitoring for any signs of increased local irritation or systemic effects is recommended if there is a concern about inadvertent overlap in therapy.

Packaging & NDC

Below are the non-prescription pack sizes of Theracare Medicated Pain Relief Patches (camphor, menthol, methyl salicylate). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should consult a physician prior to use. It is essential to keep the product out of reach of children, as used patches still contain the drug and can pose serious risks if chewed or ingested. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (800-222-1222) should be contacted.

For patients aged 12 years and older, the recommended application involves cleaning and drying the affected area before applying the patch. The patch should be removed from its film and applied to the affected area no more than 3 to 4 times daily, with a maximum application duration of 8 hours. Proper disposal of used patches is crucial to prevent accidental exposure to children and pets.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

The safety of this product during pregnancy has not been established. Pregnant patients or those planning to become pregnant should consult a healthcare provider before use. Potential risks to the fetus are not clearly defined; therefore, caution is advised. There are no specific dosage modifications for pregnant individuals. This product should only be used if clearly needed and after a thorough discussion with a healthcare provider regarding the potential risks and benefits.

Lactation

There are no specific statements regarding the use of this medication in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, specific antidotes or treatments may be indicated based on the substance involved in the overdose. Consultation with a poison control center or a medical toxicologist is recommended to guide the management of the patient effectively.

Overall, the management of overdose cases should be tailored to the individual patient, taking into account their clinical status and the specific circumstances surrounding the overdose event.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

Postmarketing experience has identified that used patches may still contain the drug product, which can lead to serious adverse effects if chewed or ingested by children or pets. This information has been reported voluntarily and through surveillance programs, highlighting the importance of proper disposal and storage of used patches to mitigate potential risks.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 800-222-1222 if the product is swallowed. It is important to instruct patients not to apply the product on wounds or damaged skin, and to avoid using it in conjunction with a heating pad.

Patients should be informed that they must not use the product if they have a known allergy to any of its ingredients. They should be counseled to discontinue use and consult a doctor if they experience rash, itching, or excessive skin irritation. Additionally, patients should be advised to stop using the product and seek medical advice if their condition worsens, if symptoms persist for more than 7 days, or if symptoms clear up and then recur within a few days.

When using the product, patients should be reminded to follow the directions carefully. They should avoid contact with eyes, mucous membranes, or rashes, and should not bandage the area tightly. It is also crucial to inform patients not to use the product simultaneously with other topical analgesics.

Finally, healthcare providers should emphasize the importance of proper disposal of used patches, ensuring that they are kept out of reach of children and pets, as these patches may still contain active ingredients that could lead to serious adverse effects if ingested.

Storage and Handling

The product is supplied in a clean, dry container designed to protect its contents from excessive moisture. It is essential to store the product in a location that is free from direct sunlight to maintain its integrity. Proper storage conditions will help ensure the product remains effective and safe for use.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Theracare Medicated Pain Relief Patches, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)